STK32A

Across TCGA pan-cancer cohorts, STK32A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK32A data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher STK32A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK32A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and LAML are the cancer types where STK32A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.059	0.779	<.001	42	view →
UCEC	DFS	Median	All	1.000	0.618	.005	34	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
BRCA	OS	Median	All	0.955	0.962	.001	10	view →
COAD	OS	Median	III,IV	0.283	0.695	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STK32A–LIHC (OS)

Open the LIHC breakdown →